Abstracts tagged "crystal-induced arthritis and gout"

Abstract Number: 866 • 2018 ACR/ARHP Annual Meeting
Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
Chio Yokose¹, Yuqing Zhang², Nicola Dalbeth³, Jie Wei¹, Savvas Nicolaou⁴, Scott Baumgartner⁵, Jia Hu⁶, Maple Fung⁵ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Formerly Ardea Biosciences, San Diego, CA, ⁶Heron Therapeutics, San Diego, CA
Background/Purpose: Gout is typically characterized as an acute monoarthritis involving the joints of the foot. However, polyarticular involvement develops, especially in advanced disease. Patterns of…
Abstract Number: 1277 • 2018 ACR/ARHP Annual Meeting
A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
Chio Yokose¹, Yuqing Zhang², Nicola Dalbeth³, Jie Wei¹, Savvas Nicolaou⁴, Scott Baumgartner⁵, Jia Hu⁶, Maple Fung⁵ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Formerly Ardea Biosciences, San Diego, CA, ⁶Heron Therapeutics, San Diego, CA
Background/Purpose: Gout is characterized by episodes of acute arthritis that are self-limiting. However, patients with gout can also develop tophi, bone erosions, joint deformity and…
Abstract Number: 2235 • 2018 ACR/ARHP Annual Meeting
Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
Chio Yokose¹, Nicola Dalbeth², Savvas Nicolaou³, Scott Baumgartner⁴, Jia Hu⁵, Maple Fung⁴, F. Joseph Simeone⁶ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²University of Auckland, Auckland, New Zealand, ³Radiology, University of British Columbia, Vancouver, BC, Canada, ⁴Formerly Ardea Biosciences, San Diego, CA, ⁵Heron Therapeutics, San Diego, CA, ⁶Department of Radiology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have demonstrated that monosodium urate (MSU) deposits on dual-energy CT (DECT) are commonly found in joints as well as tendons of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].